SNC
HZNP

Stifel Nicolaus & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Stifel Nicolaus & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$112K Buy
33,441
+1,552
+5% +$4.09K ﹤0.01% 1430
2013
Q2 		$78.4K Buy
+31,889
New +$76.5K ﹤0.01% 1351

Other funds holding HZNP

MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BPCM
Beach Point Capital Management Santa Monica, California $258M AUM 20.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Nicolaus & Co's HZNP Position: Q3 2013 in Review

Stifel Nicolaus & Co increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 4.9% in Q3 2013, buying an estimated $4.09K and bringing the position to 33,441 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1430.

Stifel Nicolaus & Co first reported a position in HZNP in Q2 2013 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold HZNP as of Q3 2013.

  • Stifel Nicolaus & Co held 33,441 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $112K as of Q3 2013.
  • Stifel Nicolaus & Co bought 1,552 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2013, an estimated $4.09K.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #1430 holding.
  • Stifel Nicolaus & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.